title: Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
authors.affiliation: Chromalloy American Kidney Center, Washington University, St. Louis, USA.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Coyne
mesh_terms: D000740:Anemia / Q000209:etiology* / Q000628:therapy*; D001803:Blood Transfusion / Q000706:statistics & numerical data; D014487:Centers for Medicare and Medicaid Services, U.S.; D002986:Clinical Trials as Topic; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000592:standards; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa